HMNC Brain Health has appointed Dr Maximilian Doebler as CEO, effective immediately, as it advances late-stage programmes for difficult-to-treat depression.

Doebler joined HMNC in 2019 and has served as Managing Director and Chief Business Officer since 2022. He has overseen development of Ketabon, an oral prolonged-release ketamine formulation for treatment-resistant depression, and Nelivabon, an oral vasopressin receptor antagonist for treatment-resistant and adjunctive major depressive disorder.